Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease

INTRODUCTION: Blepharospasm is uncommon in Parkinson's disease, especially in the peak-dose dyskinesia period. CASE PRESENTATION: We herein present the case of a patient with PD who developed blepharospasm in the peak-dose dyskinesia period. The symptom was improved by taking amantadine. CONCLU...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Qian-Ya, Zhang, Xiao-Dong, Hu, Ze-Di, Huang, Shi-Shi, Zhu, Shi-Guo, Chen, Cai-Ping, Zhang, Xiong, Wang, Jian-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561359/
https://www.ncbi.nlm.nih.gov/pubmed/36247788
http://dx.doi.org/10.3389/fneur.2022.961758
Descripción
Sumario:INTRODUCTION: Blepharospasm is uncommon in Parkinson's disease, especially in the peak-dose dyskinesia period. CASE PRESENTATION: We herein present the case of a patient with PD who developed blepharospasm in the peak-dose dyskinesia period. The symptom was improved by taking amantadine. CONCLUSION: The current report expands the phenomenology of peak-dose dykinesia in PD to include dystonic blepharospasm. This complication of levodopa therapy may respond to amantadine despite the dystonic appearance of movements.

Ejemplares similares